CAR was first identified as a receptor for Coxsackie B viruses and Adenoviruses. The protein is composed of two extracellular domains, a transmembrane domain, and a cytoplasmic tail. The extracellular domains are responsible for binding to the viral particles, facilitating their entry into the host cell .
CAR is not only a viral receptor but also plays significant roles in normal cellular functions. It is involved in the development of the heart and the lymphatic vasculature system during embryogenesis . Additionally, CAR is implicated in maintaining the integrity of epithelial cell junctions and in the regulation of cell adhesion and signaling .
CAR serves as the primary entry point for Coxsackie B viruses and Adenoviruses. These viruses bind to the membrane-distal D1 immunoglobulin domain of CAR, which facilitates their entry into the host cell . The interaction between CAR and these viruses is a critical step in the viral life cycle, leading to various diseases such as myocarditis, conjunctivitis, gastroenteritis, pneumonia, and myocarditis .
Recombinant CAR refers to the artificially synthesized version of the CAR protein, which is used in various research and therapeutic applications. Recombinant CAR can be produced using different expression systems, including bacterial, yeast, insect, and mammalian cells. This recombinant protein is utilized in studies to understand the mechanisms of viral entry, to screen for antiviral compounds, and to develop potential therapeutic interventions .
The understanding of CAR’s role in viral infections has significant clinical implications. Targeting CAR or its interaction with viruses could lead to the development of novel antiviral therapies. Additionally, CAR’s involvement in maintaining epithelial integrity and its role in embryogenesis make it a potential target for therapeutic interventions in various diseases .
In conclusion, the Coxsackievirus and Adenovirus Receptor is a multifaceted protein with critical roles in both normal cellular functions and viral infections. The recombinant form of CAR continues to be a valuable tool in research, providing insights into viral pathogenesis and potential therapeutic strategies.